TWST
Twist Bioscience Corp
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$138.10
+2.49%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$134.04
From 52W high−9.80%
Volume1.29M
Market cap$9.16B
P/E (TTM)—
P/S (TTM)21.2x
Div yield—
Key dataSep 15, 2026
Open
$134.04
From 52W high
−9.80%
Volume
1.29M
Market cap
$9.16B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−84.3x
P/E (TTM)
—
RSI (14)
57.5
MomentumView details →
1D Return
+2.49%
YTD Return
+329.32%
SummaryUpdated Jun 1, 2026
Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company founded in 2013 and headquartered in South San Francisco, California. The company went public in October 2018 and has established itself as a leader in DNA synthesis technology. Twist operates a proprietary silicon-based DNA synthesis platform that enables the manufacturing of synthetic DNA by literally "writing" DNA sequences on silicon chips, similar to how computer chips are manufactured. The company has grown from a startup to serving over 3,500 customers globally across academic, biotechnology, pharmaceutical, and industrial markets.
Similar companies
Latest newsMore news →
Brandywine Managers LLC acquired a new position in Twist Bioscience Corporation, purchasing 20,970 shares valued at approximately $2.16 million during the second quarter, as disclosed in a Form 13F filing.22d agoAnthropic published research showing its Claude models (Mythos Preview and Opus 4.8) autonomously ran protein-design campaigns, a key step in drug discovery, with designs yielding working molecules on 14 out of 15 targets at success rates above industry norms.27d agoAnthropic named Twist Bioscience Corp an independent evaluator in a new AI-driven protein design campaign.27d ago